ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteNo recent work listed

Alycia Hatashima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2978-3366; OpenAlex author ID A5090630599. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper

Papers 1

First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Co-author DOI 10.2217/fon-2021-1367 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Matthew J. Arango · 1 shared paper, 2022 · strength 0.17
- Paper First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world populatio… DOI 10.2217/fon-2021-1367 ↗
Terence Marques Williams · 1 shared paper, 2022 · strength 0.17
- Paper First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world populatio… DOI 10.2217/fon-2021-1367 ↗
Laith I. Abushahin · 1 shared paper, 2022 · strength 0.17
- Paper First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world populatio… DOI 10.2217/fon-2021-1367 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.